4-[2-(2-methyl-5-nitrophenoxy)ethyl]morpholine | 891855-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[2-(2-methyl-5-nitrophenoxy)ethyl]morpholine
• CAS: 891855-88-2
• 化学式: C₁₃H₁₈N₂O₄
• 分子量: 266.297
• InChiKey: WDHCVAFSPRFJKX-UHFFFAOYSA-N

物化性质

• 沸点：
  425.1±45.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  67.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[2-(2-methyl-5-nitrophenoxy)ethyl]morpholine 在 tin(II) chloride dihdyrate 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 1.5h， 生成 3-(3,4-dichlorophenyl)-1-{4-methyl-3-[2-(morpholin-4-yl)ethoxy]phenyl}urea
  参考文献：
  名称：

  In vitro inhibition of translation initiation by N,N′-diarylureas—potential anti-cancer agents

  摘要：

  Symmetrical N,N'-diarylureas: 1,3-bis(3,4-dichlorophenyl)-, 1,3-bis[4-chloro-3-(trifluoromethyl)phenyl]- and 1,3-bis[3,5-bis(trifluoromethyl)phenyl]urea, were identified as potent activators of the eIF2 alpha kinase heme regulated inhibitor. They reduce the abundance of the eIF2.GTP.tRNA(i)(Met) ternary complex and inhibit cancer cell proliferation. An optimization process was undertaken to improve their solubility while preserving their biological activity. Non-symmetrical hybrid ureas were generated by combining one of the hydrophobic phenyl moieties present in the symmetrical ureas with the polar 3-hydroxy-tolyl moiety. O-alkylation of the later added potentially solubilizing charge bearing groups. The new non-symmetrical N,N'-diarylureas were characterized by ternary complex reporter gene and cell proliferation assays, demonstrating good bioactivities. A representative sample of these compounds potently induced phosphorylation of eIF2 alpha and expression of CHOP at the protein and mRNA levels. These inhibitors of translation initiation may become leads for the development of potent, non-toxic, and target specific anti-cancer agents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.126
• 作为产物：
  描述：

  2-吗啉乙醇 、 5-硝基-2-甲基苯酚 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 2.17h， 以23%的产率得到4-[2-(2-methyl-5-nitrophenoxy)ethyl]morpholine
  参考文献：
  名称：

  In vitro inhibition of translation initiation by N,N′-diarylureas—potential anti-cancer agents

  摘要：

  Symmetrical N,N'-diarylureas: 1,3-bis(3,4-dichlorophenyl)-, 1,3-bis[4-chloro-3-(trifluoromethyl)phenyl]- and 1,3-bis[3,5-bis(trifluoromethyl)phenyl]urea, were identified as potent activators of the eIF2 alpha kinase heme regulated inhibitor. They reduce the abundance of the eIF2.GTP.tRNA(i)(Met) ternary complex and inhibit cancer cell proliferation. An optimization process was undertaken to improve their solubility while preserving their biological activity. Non-symmetrical hybrid ureas were generated by combining one of the hydrophobic phenyl moieties present in the symmetrical ureas with the polar 3-hydroxy-tolyl moiety. O-alkylation of the later added potentially solubilizing charge bearing groups. The new non-symmetrical N,N'-diarylureas were characterized by ternary complex reporter gene and cell proliferation assays, demonstrating good bioactivities. A representative sample of these compounds potently induced phosphorylation of eIF2 alpha and expression of CHOP at the protein and mRNA levels. These inhibitors of translation initiation may become leads for the development of potent, non-toxic, and target specific anti-cancer agents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.126

文献信息

• Metasubstituted thiazolidinones, their manufacture and use as a drug
  申请人：Schulze Klaus Volker

  公开号：US20070015759A1

  公开（公告）日：2007-01-18

  This invention involves thiazolidinone of general formula (I) and its creation and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.

  这项发明涉及一般式(I)的噻唑烷酮及其作为极化样激酶（PLK）抑制剂的创造和用途，用于治疗各种疾病。
• METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG
  申请人：SCHULZE Klause

  公开号：US20100048891A1

  公开（公告）日：2010-02-25

  Thiazolidinones of general formula (I) production thereof and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.

  通式为（I）的噻唑烷酮及其制备方法和用途，作为极化样激酶（PLK）抑制剂治疗各种疾病。
• N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION
  申请人：Aktas Bertal Huseyin

  公开号：US20120115915A1

  公开（公告）日：2012-05-10

  Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

  本文提供了抑制翻译起始的组合物和方法。描述了使用N，N'-二芳基脲和/或N，N'-二芳基硫脲化合物治疗（1）细胞增生性疾病，（2）非增生性退行性疾病，（3）病毒感染和/或（4）与病毒感染相关的疾病的组合物、方法和试剂盒。
• METASUBSTITUIERTE THIAZOLIDINONE, DEREN HERSTELLUNG UND VERWENDUNG ALS ARZNEIMITTEL
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1824834A1

  公开（公告）日：2007-08-29
• N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation
  申请人：President and Fellows of Harvard College

  公开号：US20160318857A1

  公开（公告）日：2016-11-03

  Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.